Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Interventions: HSCT with TBI Regimen, HSCT with Non-TBI Regimen; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Coronary Artery Disease
Interventions: genetic risk score for coronary risk factors; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions: JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Heart Failure
Interventions: Electronic Alert; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2030
U.S. locations: 2
States / cities: Newark, Delaware • Baltimore, Maryland

Conditions: Hypertension, Aging
Interventions: Exercise, ACE inhibitor + exercise, Thiazide diuretic + exercise, Angiotensin receptor blocker + exercise; Behavioral · Drug
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Interventions: Midodrine, Placebo pill, Abdominal compression, sham compression; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dyslipidemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 5,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more

Conditions: Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions: Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 19 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim, Fludarabine, Granulocyte Colony-Stimulating Factor, Thiotepa; Biological · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cardiovascular, Psychological Stress
Interventions: High Antioxidant Spice Blend, Trier Psychological Stressor, Placebo antioxidant concentrate; Dietary Supplement · Behavioral · Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Coronary Heart Disease
Interventions: SMT-enhanced Cardiac Rehabilitation, Standard Cardiac Rehabilitation; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 35 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Cardiovascular Risk
Interventions: Behavioral Intervention; Behavioral
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions: AI-Detected CAC Notification and Care Facilitation; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 74 Years
Enrollment: 120,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Pleasanton, California • Stanford, California + 3 more

Conditions: Stroke, Ischemic
Interventions: CHAMPS-TR; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cardiovascular Risk Factor
Interventions: Melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Living Kidney Donation, Hypertension, Nephrectomy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Transgender Women
Interventions: Placebo, Progesterone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Coronary Heart Disease, Susceptibility to, 5, Prediabetic State
Interventions: Health coaching, Genetic risk counseling, Standard risk assessment; Behavioral · Genetic
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Fairfield, California

Conditions: Cardiovascular Diseases
Interventions: Mom♥Health; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 49 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation
Interventions: Melatonin, Placebo (for Melatonin); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, COPD, Myocardial Infarction, Coronary Artery Bypass Graft, Pneumonia, Total Knee Replacement, Total Hip Replacement, Stroke
Interventions: Not listed
Lead sponsor: AdventHealth; Other
Eligibility: 21 Years and older
Enrollment: 1,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Personal Genomics for Preventive Cardiology

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure

Left Ventricular Structural Predictors of Sudden Cardiac Death

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma

Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)

Stress Management and Biomarkers of Risk in Cardiac Rehabilitation

CREATION Health Lifestyle Intervention

Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke

Melatonin and Salt on Blood Vessel Function

Assessment of Risks of Perinephric Fat Thickness to Adverse Renal Outcomes Post Donor Nephrectomy

Progesterone in Gender Affirming Hormone Therapy Study

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease

Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children

BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients

Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin

CREATION Health Readmission Risk Assessment Tool